Proactive Investors - Run By Investors For Investors

Medlab Clinical proceeding to stage II for cannabis cancer trial

The company will now proceed with stage II of the human clinical trial.
cannabis leaf and green tablets
Stage I findings showed that NanaBis™ is safe indications confirm it helps with pain reduction

Medlab Clinical Ltd (ASX:MDC) has successfully completed stage I of the NanaBis™ human trial on cancer patients at Royal North Shore Hospital.

NanaBis™ is one of two of Medlab’s cannabis-based medicines which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).

Medlab has received formal approval from the appropriate authority to proceed to stage II of the human cancer trial. 

Stage II of the clinical trial will focus on further safety but also tolerance and dose escalation.

READ: Medlab Clinical receives vital licence to export cannabis

Key data findings from stage I include that NanaBis™ is safe, is effective up to nine hours in a single dose, and early indications confirm it helps with pain reduction.

Medlab’s CEO Dr Sean Hall said: “These results confirm and validate our original hypothesis and offer a true alternative to current pain medications.

“I’m looking forward to data from stage II.

“Although pain measurement was not a key part of stage I, the early results of pain reduction while being administered NanaBis™ was very encouraging.”

In stage II, Medlab will continue with cancer patients but this time with unmanaged pain.

READ: Medlab Clinical receives positive early research results for NanoCelle™

In September, Medlab received preliminary results from research reviewing its patented delivery platform, NanoCelle™.

NanoCelle™ delivers medicine in a tiny particle form in a spray into the mouth and it is being tested using Medlab’s cannabis-based medicines, NanaBis™ and NanaBidial™.

The research concluded positively that molecules of the medicines, NanaBis™ and NanaBidial™ showed a consistent uniform pattern in nanoparticle form.

The type of work is critical as Medlab furthers its research endeavours for accepted, approved pharmaceuticals.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full MDC profile View Profile

Medlab Clinical Ltd Timeline

Related Articles

FSD Pharma facility
June 11 2019
The indoor hydroponic facility will be optimized for large-scale, medical-grade cannabis production and once complete, is expected to have over 3.9 million sq/ft available for production
November 02 2018
Back Home Medical Cannabis Corp has agreed on a 24,000-kilogram three-year production and supply agreement
November 13 2018
Ascent, viaThirty Eight Hemp Corp, will exploit the hemp market via its strategic relationship with AgTech Scientific
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use